U.S. markets close in 1 hour 26 minutes

ADC Therapeutics SA (ADCT)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
22.91-0.10 (-0.43%)
As of 2:31PM EDT. Market open.
Full screen
Loading interactive chart...
  • ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
    Business Wire

    ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting

    LAUSANNE, Switzerland, Jun 11, 2021--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that shareholders approved all of the resolutions as proposed by the Board of Directors at yesterday's Annual General Meeting (AGM).

  • ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma
    Business Wire

    ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma

    ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that abstracts on camidanlumab tesirine (Cami) and ZYNLONTA™ (loncastuximab tesirine-lpyl) have been selected for presentation at the 16th Annual International Conference on Malignant Lymphoma (ICML), which is being held virtually June 18-22, 2021.

  • ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting
    Business Wire

    ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting

    ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced updated clinical data from the ZYNLONTA™ (loncastuximab tesirine-lpyl) Phase 2 LOTIS-2 trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually J